Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.

von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H.

Circ Heart Fail. 2013 May;6(3):594-605. doi: 10.1161/CIRCHEARTFAILURE.112.000289. Review. No abstract available.

2.

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.

Vardeny O, Miller R, Solomon SD.

JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review.

PMID:
25306450
3.

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Hubers SA, Brown NJ.

Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Review.

4.

The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.

Braunwald E.

J Am Coll Cardiol. 2015 Mar 17;65(10):1029-41. doi: 10.1016/j.jacc.2015.01.033. Review.

5.

Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.

Macdonald PS.

Clin Ther. 2015 Oct 1;37(10):2199-205. doi: 10.1016/j.clinthera.2015.08.013. Epub 2015 Sep 17. Review.

PMID:
26386501
6.

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.

Jhund PS, McMurray JJ.

Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20. Review.

7.

First-in-class angiotensin receptor neprilysin inhibitor in heart failure.

Vardeny O, Tacheny T, Solomon SD.

Clin Pharmacol Ther. 2013 Oct;94(4):445-8. doi: 10.1038/clpt.2013.146. Epub 2013 Jul 19.

PMID:
23872864
8.

Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.

Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A.

Pharmacol Ther. 2004 Jun;102(3):223-41. Review.

PMID:
15246247
9.

Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.

Lillyblad MP.

Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14. Review.

PMID:
26175499
10.

Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

McKie PM, Burnett JC Jr.

Curr Heart Fail Rep. 2015 Feb;12(1):7-14. doi: 10.1007/s11897-014-0235-3. Review.

PMID:
25331110
11.

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.

12.

LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.

Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D.

Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):14-22. doi: 10.1111/bcpt.12453. Epub 2015 Sep 4. Review.

13.

Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators.

Circ Heart Fail. 2014 Nov;7(6):953-9. doi: 10.1161/CIRCHEARTFAILURE.114.001427. Epub 2014 Oct 2.

14.

LCZ696 : a new paradigm for the treatment of heart failure?

Minguet J, Sutton G, Ferrero C, Gomez T, Bramlage P.

Expert Opin Pharmacother. 2015 Feb;16(3):435-46. doi: 10.1517/14656566.2015.1000300. Review.

PMID:
25597387
15.

Sacubitril/valsartan (LCZ696) for the treatment of heart failure.

Gori M, Senni M.

Expert Rev Cardiovasc Ther. 2016;14(2):145-53. doi: 10.1586/14779072.2016.1128827. Epub 2016 Jan 8. Review.

PMID:
26642078
16.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

17.

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I.

Cardiovasc Ther. 2016 Aug;34(4):191-8. doi: 10.1111/1755-5922.12183.

18.

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.

Singh JS, Lang CC.

Vasc Health Risk Manag. 2015 Jun 1;11:283-95. doi: 10.2147/VHRM.S55630. eCollection 2015. Review.

19.

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.

McMurray JJ.

Eur J Heart Fail. 2015 Mar;17(3):242-7. doi: 10.1002/ejhf.250. Review.

20.

Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.

Sible AM, Nawarskas JJ, Alajajian D, Anderson JR.

Cardiol Rev. 2016 Jan-Feb;24(1):41-7. doi: 10.1097/CRD.0000000000000093. Review.

PMID:
26466333

Supplemental Content

Support Center